Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma
about
Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer ImmunotherapyA phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic responseMiR-21: an environmental driver of malignant melanoma?A phase II trial of stereotactic body radiotherapy with concurrent anti-PD1 treatment in metastatic melanoma: evaluation of clinical and immunologic response.A clinical and biological perspective of human myeloid-derived suppressor cells in cancer.Immunoplasticity in cutaneous melanoma: beyond pure morphology.Establishing High Dimensional Immune Signatures from Peripheral Blood via Mass Cytometry in a Discovery Cohort of Stage IV Melanoma Patients.Survival of metastatic melanoma patients after dendritic cell vaccination correlates with expression of leukocyte phosphatidylethanolamine-binding protein 1/Raf kinase inhibitory protein.Prognostic impact of high levels of circulating plasmacytoid dendritic cells in breast cancer.Disease-Associated Plasmacytoid Dendritic Cells.Circulating CD14+ HLA-DR-/low myeloid-derived suppressor cells predicted early recurrence of hepatocellular carcinoma after surgery.Purification of Immune Cell Populations from Freshly Isolated Murine Tumors and Organs by Consecutive Magnetic Cell Sorting and Multi-parameter Flow Cytometry-Based Sorting.Oncolytic Vesicular Stomatitis Virus as a Viro-Immunotherapy: Defeating Cancer with a "Hammer" and "Anvil".Prognostic role of pretreatment circulating MDSCs in patients with solid malignancies: A meta-analysis of 40 studiesWhole cell melanoma vaccine genetically modified to stem cells like phenotype generates specific immune responses to ALDH1A1 and long-term survival in advanced melanoma patients
P2860
Q26779184-85960CAB-D954-4630-81EA-8F1BBB756E9DQ32177609-06E4CBF6-229D-4762-8DCA-885E0BFF83A1Q35786021-B1350A20-5084-42C2-ACE9-D181FFF7BFAFQ37615827-E08F66BD-CB5C-4C76-A3FE-F979C8A75D6FQ38847251-C6AD513D-ED89-42D3-AC26-C7530502C106Q39067933-156025AD-2AED-4C0D-AAE1-99F360B481B0Q39093439-D95BE741-DD82-47B5-8637-77F3FA5A3039Q41976096-126C28E1-FA2C-491A-9E5A-0D59CE381B7AQ42753871-67AB87B4-9BDD-4EF8-BD6C-4FC8009B1D55Q43930865-91779C13-B313-4876-9FA5-CF17036A6924Q51759802-5689818F-1B7C-4C5D-8614-F5D07448B4ADQ52851372-66A4025B-A6E6-47A6-A97F-C41B66FC99C2Q54378300-A05DDAB6-BF0F-4A6C-A628-274451A4B376Q57138311-467A6A10-C366-44DB-A23A-C67632984FEAQ58129598-1BE794C3-E146-4016-9D73-A84CB8344988
P2860
Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Clinical significance of plasm ...... d suppressor cells in melanoma
@ast
Clinical significance of plasm ...... d suppressor cells in melanoma
@en
type
label
Clinical significance of plasm ...... d suppressor cells in melanoma
@ast
Clinical significance of plasm ...... d suppressor cells in melanoma
@en
prefLabel
Clinical significance of plasm ...... d suppressor cells in melanoma
@ast
Clinical significance of plasm ...... d suppressor cells in melanoma
@en
P2093
P2860
P1476
Clinical significance of plasm ...... d suppressor cells in melanoma
@en
P2093
Claus Bachert
Ines Chevolet
Lieve Brochez
Max Schreuer
Mireille Van Gele
Nanja van Geel
Reinhart Speeckaert
P2860
P2888
P356
10.1186/S12967-014-0376-X
P577
2015-01-16T00:00:00Z
P5875
P6179
1011342379